Ibrutinib-Venetoclax-Obinutuzumab for Richter Transformation
May 5, 2025
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
The first-line combination pirtobrutinib, venetoclax, and obinutuzumab produces deep remissions in the majority of patients with CLL.
Data suggests that patients with CLL who are on venetoclax plus obinutuzumab and reach undetectable MRD may be able to discontinue therapy early.
Acalabrutinib, venetoclax, and obinutuzumab is a highly active, time-limited frontline therapy for patients with high-risk CLL.
Acalabrutinib plus obinutuzumab had a 100 percent response rate at 14 months and a deep reduction of disease in the bone marrow in treatment-naive CLL.
An interim analysis of the AMPLIFY trial comparing acalabrutinib and venetoclax with or without obinutuzumab for CLL shows improvements in patient survival.
Obinutuzumab can be given alone or in combination with many other medications to treat CLL or SLL.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911